a, An HSQC spectrum of the Abl/imatinib complex with (red) and without (black) GNF-2 (top) showing chemical shift changes induced by ligand binding. Mapping of the chemical shift changes to the structure of the Abl/imatinib complex (PDB entry 1OPK8 bottom) identifies the myristate pocket as the GNF-2 binding site. The size of the spheres is proportional to the magnitude of the chemical shift changes. b, Same as a except myristic acid used instead of GNF-2.

a, Abl kinase is indicated in green (helices indicated with transparent cylinders) with the bent part of the I-helix in yellow, GNF-2 resistance mutations in pink, and GNF-2 carbons in cyan. H-bonding and other polar interactions are indicated by dotted red lines. b, Superposition of the Abl–imatinib–myr (white), Abl-imatinib-GNF-2 (green and yellow), Abl-imatinib (red) structures. GNF-2 is colored in cyan and myristic acid in magenta.

a, Effect of various concentrations of GNF-2, imatinib, or combinations of both on the number of emerging Ba/F3.Bcr-Abl resistant clones (shown on the top of each bar). b, Mutations indicated by red spheres on Abl with size proportional to the degree of resistance (PDB ID 1OPK8, amino acid residues numbering of Abl 1a). c, IC₅₀ for growth inhibition by imatinib or GNF-2 for wild-type and mutant Bcr-Abl transformed Ba/F3 cells. The number of colonies that emerge after 12 days in the presence of 20 µM GNF-2 is indicated.

a, Effects of GNF-5, nilotinib and varying concentrations of GNF-5 in combination with nilotinib (0.3–10 µM) on the proliferation of T315I Bcr-Abl Ba/F3 cells. The combination curve (red, as well in Fig 4c) contains twice the total drug concentration of the single agent curves due to both drugs being present. b, Inhibition of Bcr-Abl autophosphorylation was determined by Bcr-Abl immunoprecipitation, followed by a immunoblot for phospho-Tyr (Y412)1, phospho-STAT5 (Y694) and total Bcr-Abl (antibody K-12) from cell lystates obtained after treatment of T315I Bcr-Abl expressing Ba/F3 with 10 µM of nilotinib and increasing concentrations of GNF-5 (0, 0.5, 5 and 10 µM) for 90 min. c, Percent inhibition of T315I Abl kinase by nilotinib and GNF-5 or the combination. d, IC₅₀ for inhibition of wild-type, E505K and T315I Abl kinase activity by GNF-5, nilotinib or the combination at an ATP concentration of 20 µM.

a, Deuterium uptake curves for the peptides 306–316 and 506–515. The y-axis maximum corresponds to the theoretical maximum amount of deuterium that could be incorporated into this peptide. No alterations in deuterium incorporation were seen with the E505K mutant whereas exchange was affected by GNF-5 binding to the wild-type protein. b, Location of the peptides that showed differences in deuterium incorporation mapped on the crystal structure of active Abl (PDB: 2F4J). This crystal structure was chosen because in the absence of myristoylation (as for the protein used here), Abl protein is believed to be in this conformation23. Major changes (colored magenta) were defined as a difference between exchange curves of 1.0 Da or more. Minor changes (colored yellow) were 0.4–1.0 Da. No changes (colored grey) were differences of 0.0–0.4 Da.

a, Images of whole body luminescence of wild-type Bcr-Abl and luciferase expressing Ba/F3 cells on days five and seven after treatment with vehicle, GNF-5 50 mg/kg and 100 mg/kg b.i.d. b, Average white blood cell counts for vehicle, nilotinib, GNF-5, or combination treatments in the T315I Bcr-Abl bone marrow transplantation efficacy study. c, Spleen weight for vehicle, nilotinib, GNF-5, or combination treatments in the T315I Bcr-Abl bone marrow transplantation efficacy study. d, Quantification of p-STAT5-positive cells by flow cytometry in the different treatment groups after repeated doses. e, Time course inhibition of STAT5 phosphorylation after a single dose of GNF-5 and nilotinib combination. f, Kaplan-Meier plot showing survival of mice (n = 5 mice per group) transplanted with T315I Bcr-Abl transduced bone marrow and treated with vehicle (solid line), 75 mg/kg b.i.d. GNF-5 (dotted line), 50 mg/kg b.i.d. nilotinib (dots and dashes), or a combination of 75 mg/kg b.i.d. GNF-5 plus 50 mg/kg b.i.d. nilotinib (dashed line). Compound dosing was initiated on day 11 post-transplantation and discontinued on day 50 (indicated by arrows). Error bars are s.e.m.